Abstract:Various molecular analytical techniques have providedmore and more information which is necessary for theaccurate classiﬁcation of diseases. Such informationhas enabled researchers to shift from morphology-based classiﬁcation to molecular characteristics-basedclassiﬁcation, also known as molecular classiﬁcation.Molecular classiﬁcations of diseases can be carried outat the DNA, RNA, and protein levels. At the DNA level,for example,molecular classiﬁcation canbe done basedon genetic mutation, polymorphisms, cytogeneticchanges in genomes or DNA methylation differences.Classiﬁcation based on different mRNA expressionproﬁles is currently a key research approach. Since itsintroduction in the 1990s, biochip technology, as a high-throughput large-scale analytic technology, has beenincreasingly applied in research on functional genomics,disease genomics, and pharmacogenomics. Rapidadvances in molecular classiﬁcation have shed lighton the establishment of guidelines for the molecularclassiﬁcation of tumors and personalized diagnosis andtreatment.Tumors are a heterogeneous group of systemicdiseases that develop in multiple steps/phases.Although loss of genomic stability and evading immunedestruction are two milestone events that may beobserved throughout the occurrence and developmentof tumors, the pathogenesis of tumors differs widelyamong different cancers and individuals. Dramaticadvances in basic research over the last 30 yearshave enabled practitioners to understand the pathogen-esis of malignancies at the molecular level and providedsolid bases for the prevention and treatment of tumors.The prognoses of most malignancies, advancedmalignant tumors in particular, have unfortunately notbeen fundamentally improved.Histopathology has long been the “gold standard” oftumor diagnosis and the basis for clinical treatment;however, for tumors of the same phases and stages,treatment responses and prognoses may differ vastlyamong patients even after application of the sametherapeutic strategy. In fact, malignant tumors are highlyheterogeneous at the molecular level. Tumors with thesame morphology may contain varied changes inmolecular genetics, resulting in diversity in treatmentresponses and prognoses. Individualized treatmentbased on molecular differences is thus a new directionfor tumor treatment, and molecular classiﬁcation is thebasis of individualized therapy.One of the challenges in the new century is todetermine speciﬁc targeted therapies aimed at tumortypes with the same pathological origin so as tomaximize the efﬁcacy and minimize the toxicity oftherapy. Accurate classiﬁcation of tumors will obviouslybe vital toward achieving this endeavor.In our laboratory, we employed high-throughputmolecular techniques, such as gene chip and tissuemicroarray to detect 18 molecular markers by immuno-histochemistry and determined that the combinedexpression levels of seven proteins, including latencymembrane protein 1 (LMP1), CD147, caveolin-1,phospho-P70S6 kinase, survivin, matrix metalloprotei-nase 11 (MMP11), and secreted protein acidic and richin cysteine (SPARC), in tumors, together with patientsex, can distinguish patients with nasopharyngealcarcinoma (NPC) into low- and high-risk groups forprediction of NPC survival [1]. For these two groups ofpatients, the division indicates the clinical application ofindividualizedtherapy soasto preventover-treatment ofthe low-risk group and ensure appropriate treatment ofthe high-risk group. We also detected cancer stem cellsin NPC and proposed that genomic instability and DNAdamage are among the main causes of cancer stem cellformation [2,3]. In fact, the expressions of manyimportant genes, including p63, RASSF1A, VEGF,CCND1, and Hsp70, signiﬁcantly differ in NPC tissue

Molecular Genetic Analysis in Surgical Pathology

[Molecular pathological analysis through the ages]

Molecular testing in cytology

Molecular pathology of soft tissue and bone tumors. A review

Molecular techniques in cytopathology practice

Avoiding Pitfalls in Molecular Genetic Testing

Avoiding pitfalls in molecular genetic testing: case studies of high-resolution array comparative genomic hybridization testing in the definitive diagnosis of Mowat-Wilson syndrome.

Molecular analyses in the diagnosis and prediction of prognosis in non-GIST soft tissue sarcomas: A systematic review and meta-analysis

Pathologic progress of diagnosis and subtypes of lung cancer associated with molecular-targeted therapy

Stimulated Raman Scattering Micro-dissection Sequencing (SMD-Seq) for Morphology-specific Genomic Analysis of Oral Squamous Cell Carcinoma

Molecular Classification of Cancer and Molecular Targeted Therapy

Molecular Cytology of the Respiratory Tract and Pleura

Gene expression array analysis to determine tissue of origin of carcinoma of unknown primary

Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis

Application of Immunohistochemistry in Undifferentiated Neoplasms: A Practical Approach.

Transpathology: molecular imaging-based pathology

Molecular diagnostics of infectious disease: Detection and characterization of microbial agents in cytology samples

Molecular diagnosis in clinical parasitology: When and why?

The current and future applications of in situ hybridization technologies in anatomical pathology

[Molecular diagnosis of infectious disease]

Detection of SYT - SSX Fusion Gene Transcripts in Synovial Sarcoma and Its Correlation with Histological Phenotypes